| Literature DB >> 1923917 |
B G Wells1, C C Chu, R Johnson, C Nasdahl, M A Ayubi, E Sewell, P Statham.
Abstract
Three patients with a DSM-III-R diagnosis of posttraumatic stress disorder were successfully treated with buspirone in final maximum dosages ranging from 35-60 mg daily. The onset of clinical efficacy ranged from 5-29 days. Symptoms that improved included anxiety, insomnia, flashbacks, and depressed mood. Patients experienced no side effects. Serotonin partial agonist effects are a possible mechanism underlying buspirone's efficacy.Entities:
Mesh：
Substances：
Year: 1991 PMID： 1923917
Source DB: PubMed Journal: Pharmacotherapy ISSN： 0277-0008 Impact factor: 4.705